Logo image of CTMX

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

USA - NASDAQ:CTMX - US23284F1057 - Common Stock

2.06 USD
+0.08 (+4.04%)
Last: 9/22/2025, 9:37:49 PM
2.06 USD
0 (0%)
After Hours: 9/22/2025, 9:37:49 PM
Fundamental Rating

4

Taking everything into account, CTMX scores 4 out of 10 in our fundamental rating. CTMX was compared to 538 industry peers in the Biotechnology industry. CTMX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CTMX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year CTMX was profitable.
In the past year CTMX has reported a negative cash flow from operations.
CTMX had negative earnings in 4 of the past 5 years.
In the past 5 years CTMX reported 4 times negative operating cash flow.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 27.41%, CTMX belongs to the top of the industry, outperforming 97.96% of the companies in the same industry.
CTMX's Return On Equity of 40.02% is amongst the best of the industry. CTMX outperforms 98.14% of its industry peers.
CTMX has a Return On Invested Capital of 25.08%. This is amongst the best in the industry. CTMX outperforms 97.96% of its industry peers.
Industry RankSector Rank
ROA 27.41%
ROE 40.02%
ROIC 25.08%
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

1.3 Margins

CTMX's Profit Margin of 34.01% is amongst the best of the industry. CTMX outperforms 96.65% of its industry peers.
CTMX's Operating Margin of 30.56% is amongst the best of the industry. CTMX outperforms 96.84% of its industry peers.
Industry RankSector Rank
OM 30.56%
PM (TTM) 34.01%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CTMX is creating value.
CTMX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CTMX has been increased compared to 5 years ago.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CTMX has an Altman-Z score of 0.69. This is a bad value and indicates that CTMX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.69, CTMX is doing good in the industry, outperforming 62.64% of the companies in the same industry.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.69
ROIC/WACC2.55
WACC9.85%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

CTMX has a Current Ratio of 4.20. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
CTMX's Current ratio of 4.20 is in line compared to the rest of the industry. CTMX outperforms 48.14% of its industry peers.
A Quick Ratio of 4.20 indicates that CTMX has no problem at all paying its short term obligations.
With a Quick ratio value of 4.20, CTMX perfoms like the industry average, outperforming 49.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 4.2
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 306.43% over the past year.
CTMX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.01%.
The Revenue has been growing by 19.15% on average over the past years. This is quite good.
EPS 1Y (TTM)306.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.75%
Revenue 1Y (TTM)18.01%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-25.71%

3.2 Future

The Earnings Per Share is expected to decrease by -6.72% on average over the next years.
Based on estimates for the next years, CTMX will show a small growth in Revenue. The Revenue will grow by 1.51% on average per year.
EPS Next Y-95.5%
EPS Next 2Y-67.9%
EPS Next 3Y-45.87%
EPS Next 5Y-6.72%
Revenue Next Year-22.75%
Revenue Next 2Y-40.74%
Revenue Next 3Y-37.72%
Revenue Next 5Y1.51%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 3.61, the valuation of CTMX can be described as very cheap.
Based on the Price/Earnings ratio, CTMX is valued cheaper than 98.70% of the companies in the same industry.
When comparing the Price/Earnings ratio of CTMX to the average of the S&P500 Index (27.41), we can say CTMX is valued rather cheaply.
CTMX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 3.61
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CTMX is valued cheaply inside the industry as 99.26% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.33
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

CTMX's earnings are expected to decrease with -45.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.9%
EPS Next 3Y-45.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (9/22/2025, 9:37:49 PM)

After market: 2.06 0 (0%)

2.06

+0.08 (+4.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners49.81%
Inst Owner Change194.58%
Ins Owners0.63%
Ins Owner Change3.95%
Market Cap339.71M
Analysts84.62
Price Target5.87 (184.95%)
Short Float %18.56%
Short Ratio10.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.1%
Min EPS beat(2)98.72%
Max EPS beat(2)113.47%
EPS beat(4)4
Avg EPS beat(4)141.82%
Min EPS beat(4)98.72%
Max EPS beat(4)215.22%
EPS beat(8)8
Avg EPS beat(8)146.11%
EPS beat(12)10
Avg EPS beat(12)101.81%
EPS beat(16)11
Avg EPS beat(16)73.27%
Revenue beat(2)2
Avg Revenue beat(2)42.82%
Min Revenue beat(2)23.76%
Max Revenue beat(2)61.87%
Revenue beat(4)4
Avg Revenue beat(4)66.28%
Min Revenue beat(4)23.76%
Max Revenue beat(4)92.34%
Revenue beat(8)8
Avg Revenue beat(8)60.6%
Revenue beat(12)10
Avg Revenue beat(12)36.87%
Revenue beat(16)10
Avg Revenue beat(16)12.56%
PT rev (1m)0%
PT rev (3m)4.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50.91%
EPS NY rev (1m)0%
EPS NY rev (3m)9.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)63.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)19.17%
Valuation
Industry RankSector Rank
PE 3.61
Fwd PE N/A
P/S 2.41
P/FCF N/A
P/OCF N/A
P/B 2.83
P/tB 2.87
EV/EBITDA 1.33
EPS(TTM)0.57
EY27.67%
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.86
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.41%
ROE 40.02%
ROCE 31.75%
ROIC 25.08%
ROICexc N/A
ROICexgc N/A
OM 30.56%
PM (TTM) 34.01%
GM N/A
FCFM N/A
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 15.57%
Cap/Sales 0.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 4.2
Altman-Z 0.69
F-Score6
WACC9.85%
ROIC/WACC2.55
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)306.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.75%
EPS Next Y-95.5%
EPS Next 2Y-67.9%
EPS Next 3Y-45.87%
EPS Next 5Y-6.72%
Revenue 1Y (TTM)18.01%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-25.71%
Revenue Next Year-22.75%
Revenue Next 2Y-40.74%
Revenue Next 3Y-37.72%
Revenue Next 5Y1.51%
EBIT growth 1Y654.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.83%
OCF growth 3YN/A
OCF growth 5YN/A